F.D.A. Approves Drug for Persistently Deadly Form of Lung Cancer

The FDA has approved a new drug, tarlatamab (Imdelltra), by Amgen for patients with a specific type of terminal small cell lung cancer, who have no other treatment options and a life expectancy of about four to five months. This drug has shown promising results by tripling the life expectancy to 14 months for those treated. Medical experts believe tarlatamab represents a significant breakthrough after years without advancements in treating this deadly cancer.